Dr. Bray Links

Wednesday, October 28, 2015

PSA Tests Cut Metastatic Prostate Cancer Rate by 50%

Screening for early cancer detection may reduce the rate of related metastatic disease, but not always. In a perspective published today in the New England Journal of Medicine, the authors describe trends in metastatic breast cancer and prostate cancer prior to and more than a decade after the widespread use of mammography — a radiographic test — and prostate-specific antigen (PSA) testing — a blood test.

The trends are startlingly different. The incidence of metastatic prostate cancer fell by approximately 50% within 7 years of the start of widespread PSA use in 1990; however, rates of metastatic breast cancer remained remarkably stable following the initiation of widespread mammography screening in women from 1985 to the current day.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.